EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection

Peng Li, Mohammad Abdallah, Yuxin Yao, Rekha Shandre Mugan, Thomas J Payne, Stewart A Fabb, Colin W Pouton, Natalie L Trevaskis

Journal of Controlled Release · 2026-12 · 400 · 115491

DOI: 10.1016/j.jconrel.2026.115491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Peng Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticle (LNP) formulations have enabled the in vivo delivery of messenger ribonucleic acid (mRNA) vaccines and therapeutics yet the delivery of RNA remains relatively inefficient. In order to improve LNP design there is a need to better understand how current mRNA-LNP formulations are trafficked and expressed in vivo. Importantly, no prior work has quantified mRNA-LNP transport through lymphatics. In the current study we profile the thoracic lymph uptake, plasma pharmacokinetics (PK), and tissue protein expression after intravenous (IV) and subcutaneous (SC) administration in rats of three common LNP formulations (ALC-0315, SM-102 and MC3 ionizable lipids) containing muGFP-P2A-nLuc reporter mRNA. After IV administration, the SM-102 and MC3 LNP formulations provided the most effective protection of mRNA in plasma. Despite this, tissue NanoLuc® Luciferase (nLuc) expression at 32 h post-dosing was relatively similar across formulations with highest expression seen in the liver and spleen. After SC injection, all formulations supported relatively low bioavailability of mRNA (0.42-0.87% dose) and slightly higher bioavailability of ionizable and PEG lipid (

Schlagwörter

Stichwörter der Autor:innen

BiodistributionIntravenous injectionIonizable lipidLipid nanoparticleLymphaticsPharmacokineticsSubcutaneous injectionmRNA

Autor:innen und Institutionen

  • Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
  • Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; Baker Heart and Diabetes Institute, Melbourne, VIC 3000, Australia. Electronic add…

Zitieren

APA

Li, P., Abdallah, M., Yao, Y., Mugan, R. S., Payne, T. J., Fabb, S. A., Pouton, C. W., & Trevaskis, N. L. (2026). Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection. Journal of Controlled Release, 400, 115491. https://doi.org/10.1016/j.jconrel.2026.115491

Vancouver

Li P, Abdallah M, Yao Y, Mugan RS, Payne TJ, Fabb SA, et al. Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection. Journal of Controlled Release. 2026;400:115491. doi:10.1016/j.jconrel.2026.115491

BibTeX
@article{Li2026,
  author = {Li, Peng and Abdallah, Mohammad and Yao, Yuxin and Mugan, Rekha Shandre and Payne, Thomas J and Fabb, Stewart A and Pouton, Colin W and Trevaskis, Natalie L},
  title = {Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {400},
  pages = {115491},
  doi = {10.1016/j.jconrel.2026.115491}
}
Kostenlos starten →